US20160166559A1 - Deuterated analogs of pridopidine useful as dopaminergic stabilizers - Google Patents

Deuterated analogs of pridopidine useful as dopaminergic stabilizers Download PDF

Info

Publication number
US20160166559A1
US20160166559A1 US14/968,522 US201514968522A US2016166559A1 US 20160166559 A1 US20160166559 A1 US 20160166559A1 US 201514968522 A US201514968522 A US 201514968522A US 2016166559 A1 US2016166559 A1 US 2016166559A1
Authority
US
United States
Prior art keywords
deuterium
pharmaceutical composition
represent hydrogen
represent
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/968,522
Inventor
Clas Sonesson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceuticals International GmbH
Original Assignee
Teva Pharmaceuticals International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceuticals International GmbH filed Critical Teva Pharmaceuticals International GmbH
Priority to US14/968,522 priority Critical patent/US20160166559A1/en
Publication of US20160166559A1 publication Critical patent/US20160166559A1/en
Priority to US15/960,041 priority patent/US20180235950A1/en
Priority to US16/133,192 priority patent/US10799492B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/24—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms

Definitions

  • the present invention provides novel deuterated analogs of Pridopidine, i.e. 4-(3-methanesulfonyl-phenyl)-1-propyl-piperidine.
  • Pridopidine is a drug substance currently in clinical development for the treatment of Huntington's disease.
  • the invention relates to pharmaceutical compositions comprising a deuterated analog of Pridopidine of the invention, and to therapeutic applications of these analogs.
  • Deuterium also called “heavy hydrogen” is a stable isotope of hydrogen with a natural abundance in the oceans of Earth of approximately one atom in 6,500 of hydrogen ( ⁇ 154 ppm). Deuterium thus accounts for approximately 0.0154% (alternately, on a mass basis: 0.0308%) of all naturally occurring hydrogen in the oceans on Earth.
  • the nucleus of deuterium called a deuteron, contains one proton and one neutron, whereas the hydrogen nucleus contains no neutron.
  • Deuterium forms bonds with carbon that vibrate at a lower frequency and are thus stronger than C—H bonds. Therefore “heavy hydrogen” versions of drugs may be more stable towards degradation and last longer in the organism. Incorporating deuterium in place of hydrogen thus may improve the pharmacodynamic and pharmacokinetic profiles of drugs, thus modifying the metabolic fate, while retaining the pharmacologic activity and selectivity of physiologically active compounds. Deuterated drugs thus may positively impact safety, efficacy and/or tolerability.
  • Pridopidine i.e. 4-(3-methanesulfonyl-phenyl)-1-propyl-piperidine, a dopaminergic stabilizer currently in clinical development for the treatment of Huntington's disease.
  • the compound is described in e.g. WO 01/46145, and in e.g. WO 2006/040155 an alternative method for its synthesis is described.
  • the object of the present invention is to provide analogs of Pridopidine with improved pharmacodynamic and pharmacokinetic profiles.
  • the invention provides a partially or fully deuterated analog of 4-(3-methanesulfonyl-phenyl)-1-propyl-piperidine as represented by Formula 1, below.
  • the invention provides a pharmaceutical composition, comprising a therapeutically effective amount of a deuterated analog of 4-(3-methanesulfonyl-phenyl)-1-propyl-piperidine of the invention, or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, excipient or diluent.
  • the invention relates to the use of the deuterated analog of 4-(3-methanesulfonyl-phenyl)-1-propyl-piperidine of the invention as a medicament, or for the manufacture of a medicament.
  • the invention provides a method for treatment, prevention or alleviation of a dopamine mediated disorder of a living animal body, including a human, which method comprises the step of administering to such a living animal body in need thereof a therapeutically effective amount of a deuterated analog of 4-(3-methanesulfonyl-phenyl)-1-propyl-piperidine according to the invention, or a pharmaceutically acceptable salt thereof.
  • the present invention provides deuterated analogs of Pridopidine.
  • the deuterated analog of the invention may be a fully or partially deuterium substituted derivative.
  • the deuterated analog of the invention may in particular be characterised by Formula I
  • R 1 -R 23 represents deuterium (D).
  • R 1 -R 23 represent hydrogen (H).
  • the abundance of deuterium at that position is at least 3340 times greater (i.e. at least 50.1% incorporation of deuterium) than the natural abundance of deuterium.
  • the abundance of deuterium at that position is at least 3500 (52.5% deuterium incorporation), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation).
  • the deuterated analog of the invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein
  • R 1 -R 2 represent deuterium (D);
  • R 3 -R 23 represent hydrogen (H).
  • the deuterated analog of the invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein
  • R 1 -R 7 represents deuterium (D).
  • R 1 -R 23 represent hydrogen (H).
  • the deuterated analog of the invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein
  • R 1 -R 7 represent deuterium (D).
  • R 8 -R 23 represent hydrogen (H).
  • the deuterated analog of the invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein
  • R 8 , R 9 , R 10 and R 11 represent deuterium (D);
  • R 1 -R 7 and R 12 -R 23 represent hydrogen (H).
  • the deuterated analog of the invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein
  • R 12 represents deuterium (D).
  • R 1 -R 11 and R 13 -R 23 represent hydrogen (H).
  • the deuterated analog of the invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein
  • R17-R 20 represent deuterium (D);
  • R 1 -R 16 and R 21 -R 23 represent hydrogen (H).
  • the deuterated analog of the invention may be provided in any form suitable for the intended administration. Suitable forms include pharmaceutically (i.e. physiologically) acceptable salts, and pre- or prodrug forms of the deuterated analog of the invention.
  • salts include, without limitation, the non-toxic inorganic and organic acid addition salts such as the hydrochloride, the hydrobromide, the nitrate, the perchlorate, the phosphate, the sulphate, the formate, the acetate, the aconate, the ascorbate, the benzenesulphonate, the benzoate, the cinnamate, the citrate, the embonate, the enantate, the fumarate, the glutamate, the glycolate, the lactate, the maleate, the malonate, the mandelate, the methanesulphonate, the naphthalene-2-sulphonate, the phthalate, the salicylate, the sorbate, the stearate, the succinate, the tartrate, the toluene-p-sulphonate, and the like.
  • Such salts may be formed by procedures well known and described in the art.
  • acids such as oxalic acid, which may not be considered pharmaceutically acceptable, may be useful in the preparation of salts useful as intermediates in obtaining a deuterated analog of the invention and its pharmaceutically acceptable acid addition salt.
  • Examples of pharmaceutically acceptable cationic salts of a deuterated analog of the invention include, without limitation, the sodium, the potassium, the calcium, the magnesium, the zinc, the aluminium, the lithium, the choline, the lysinium, and the ammonium salt, and the like, of a deuterated analog of the invention containing an anionic group.
  • Such cationic salts may be formed by procedures well known and described in the art.
  • the deuterated analog of the invention may be provided in dissoluble or indissoluble forms together with a pharmaceutically acceptable solvent such as water, ethanol, and the like.
  • Dissoluble forms may also include hydrated forms such as the monohydrate, the dihydrate, the hemihydrate, the trihydrate, the tetrahydrate, and the like. In general, the dissoluble forms are considered equivalent to indissoluble forms for the purposes of this invention.
  • the deuterated analog of the invention may be prepared by conventional methods for chemical synthesis, e.g. those described in the working examples.
  • the starting materials for the processes described in the present application are known or may readily be prepared by conventional methods from commercially available chemicals.
  • one compound of the invention may be converted to another compound of the invention using conventional methods.
  • the end products of the reactions described herein may be isolated by conventional techniques, e.g. by extraction, crystallisation, distillation, chromatography, etc.
  • WO 01/46145, WO 01/46146, WO 2005/121087, WO 2007/042295 WO 2008/127188 and WO 2008/155357 all describe substituted 4-phenyl-N-alkyl-piperazines and 4-phenyl-N-alkyl-piperidines, reported to be modulators of dopamine neurotransmission, and to be useful in treatment of symptoms of various disorders of the central nervous system.
  • the deuterated analog of the invention is considered useful for the same medical indications as described in these publications, and these publications therefore are incorporated by reference.
  • Neurological indications contemplated according to these publications include the treatment of Huntington's disease and other movement disorders, as well as movement disorders induced by drugs.
  • the invention relates to the use of the deuterated analog of the invention for use as a medicament for the treatment of Huntington's disease.
  • the invention provides deuterated analogs for use as medicaments. Therefore, in another aspect, the invention provides novel pharmaceutical compositions comprising a therapeutically effective amount of the compound of the invention.
  • a deuterated analog of the invention for use in therapy may be administered in the form of the raw compound, it is preferred to introduce the active ingredient, optionally in the form of a physiologically acceptable salt, in a pharmaceutical composition together with one or more adjuvants, excipients, carriers, buffers, diluents, and/or other customary pharmaceutical auxiliaries.
  • compositions of the invention may in particular be formulated as described in WO 01/46145.
  • the dose administered must of course be carefully adjusted to the age, weight and condition of the individual being treated, as well as the route of administration, dosage form and regimen, and the result desired, and the exact dosage should of course be determined by the practitioner.
  • compositions containing of from about 1 to about 500 mg of active ingredient per individual dose, preferably of from about 10 to about 100 mg, most preferred of from about 25 to about 50 mg, are suitable for therapeutic treatments.
  • the daily dose will preferably be administered in individual dosages 1 to 4 times daily.
  • the invention provides a method for the treatment, prevention or alleviation of a dopamine mediated disorder of a living animal body, including a human, which method comprises the step of administering to such a living animal body in need thereof a therapeutically effective amount of the deuterated analog of the invention.
  • the dopamine mediated disorder is Huntington's disease.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

In other aspects the invention relates to pharmaceutical compositions comprising a deuterated analog of Pridopidine of the invention, and to therapeutic applications of these analogs.

Description

    FIELD OF THE INVENTION
  • The present invention provides novel deuterated analogs of Pridopidine, i.e. 4-(3-methanesulfonyl-phenyl)-1-propyl-piperidine. Pridopidine is a drug substance currently in clinical development for the treatment of Huntington's disease.
  • In other aspects the invention relates to pharmaceutical compositions comprising a deuterated analog of Pridopidine of the invention, and to therapeutic applications of these analogs.
    • BACKGROUND OF THE INVENTION
  • Deuterium, also called “heavy hydrogen”, is a stable isotope of hydrogen with a natural abundance in the oceans of Earth of approximately one atom in 6,500 of hydrogen (˜154 ppm). Deuterium thus accounts for approximately 0.0154% (alternately, on a mass basis: 0.0308%) of all naturally occurring hydrogen in the oceans on Earth. The nucleus of deuterium, called a deuteron, contains one proton and one neutron, whereas the hydrogen nucleus contains no neutron.
  • Deuterium forms bonds with carbon that vibrate at a lower frequency and are thus stronger than C—H bonds. Therefore “heavy hydrogen” versions of drugs may be more stable towards degradation and last longer in the organism. Incorporating deuterium in place of hydrogen thus may improve the pharmacodynamic and pharmacokinetic profiles of drugs, thus modifying the metabolic fate, while retaining the pharmacologic activity and selectivity of physiologically active compounds. Deuterated drugs thus may positively impact safety, efficacy and/or tolerability.
  • Pridopidine, i.e. 4-(3-methanesulfonyl-phenyl)-1-propyl-piperidine, a dopaminergic stabilizer currently in clinical development for the treatment of Huntington's disease. The compound is described in e.g. WO 01/46145, and in e.g. WO 2006/040155 an alternative method for its synthesis is described.
    • SUMMARY OF THE INVENTION
  • The object of the present invention is to provide analogs of Pridopidine with improved pharmacodynamic and pharmacokinetic profiles.
  • Therefore, in its first aspect the invention provides a partially or fully deuterated analog of 4-(3-methanesulfonyl-phenyl)-1-propyl-piperidine as represented by Formula 1, below.
  • In another aspect the invention provides a pharmaceutical composition, comprising a therapeutically effective amount of a deuterated analog of 4-(3-methanesulfonyl-phenyl)-1-propyl-piperidine of the invention, or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, excipient or diluent.
  • Viewed from another aspect the invention relates to the use of the deuterated analog of 4-(3-methanesulfonyl-phenyl)-1-propyl-piperidine of the invention as a medicament, or for the manufacture of a medicament.
  • In a further aspect the invention provides a method for treatment, prevention or alleviation of a dopamine mediated disorder of a living animal body, including a human, which method comprises the step of administering to such a living animal body in need thereof a therapeutically effective amount of a deuterated analog of 4-(3-methanesulfonyl-phenyl)-1-propyl-piperidine according to the invention, or a pharmaceutically acceptable salt thereof.
  • Other aspects of the invention will be apparent to the person skilled in the art from the following detailed description and examples.
    • DETAILED DESCRIPTION OF THE INVENTION Deuterated Analogs Of Pridopidine
  • In its first aspect the present invention provides deuterated analogs of Pridopidine. The deuterated analog of the invention may be a fully or partially deuterium substituted derivative. The deuterated analog of the invention may in particular be characterised by Formula I
  • Figure US20160166559A1-20160616-C00001
  • or a pharmaceutically acceptable salt thereof, wherein
  • at least one of R1-R23 represents deuterium (D); and
  • the remaining of R1-R23 represent hydrogen (H).
  • In the context of this invention, when a particular position is designated as holding deuterium, it is understood that the abundance of deuterium at that position is substantially greater than the natural abundance of deuterium, which is about 0.015%.
  • In a preferred embodiment the abundance of deuterium at that position is at least 3340 times greater (i.e. at least 50.1% incorporation of deuterium) than the natural abundance of deuterium. In other preferred embodiments of the invention the abundance of deuterium at that position is at least 3500 (52.5% deuterium incorporation), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation).
  • In a preferred embodiment the deuterated analog of the invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein
  • R1-R2 represent deuterium (D); and
  • all of R3-R23 represent hydrogen (H).
  • In another preferred embodiment the deuterated analog of the invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein
  • at least one of R1-R7 represents deuterium (D); and
  • the remaining of R1-R23 represent hydrogen (H).
  • In a third preferred embodiment the deuterated analog of the invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein
  • all of R1-R7 represent deuterium (D); and
  • all of R8-R23 represent hydrogen (H).
  • In a fourth preferred embodiment the deuterated analog of the invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein
  • R8, R9, R10 and R11 represent deuterium (D); and
  • all of R1-R7 and R12-R23 represent hydrogen (H).
  • In a fifth preferred embodiment the deuterated analog of the invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein
  • R12 represents deuterium (D); and
  • all of R1-R11 and R13-R23 represent hydrogen (H).
  • In a sixth preferred embodiment the deuterated analog of the invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein
  • R17-R20 represent deuterium (D); and
  • all of R1-R16 and R21-R23 represent hydrogen (H).
  • Any combination of two or more of the embodiments described herein is considered within the scope of the present invention.
    • Pharmaceutically Acceptable Salts
  • The deuterated analog of the invention may be provided in any form suitable for the intended administration. Suitable forms include pharmaceutically (i.e. physiologically) acceptable salts, and pre- or prodrug forms of the deuterated analog of the invention.
  • Examples of pharmaceutically acceptable salts include, without limitation, the non-toxic inorganic and organic acid addition salts such as the hydrochloride, the hydrobromide, the nitrate, the perchlorate, the phosphate, the sulphate, the formate, the acetate, the aconate, the ascorbate, the benzenesulphonate, the benzoate, the cinnamate, the citrate, the embonate, the enantate, the fumarate, the glutamate, the glycolate, the lactate, the maleate, the malonate, the mandelate, the methanesulphonate, the naphthalene-2-sulphonate, the phthalate, the salicylate, the sorbate, the stearate, the succinate, the tartrate, the toluene-p-sulphonate, and the like. Such salts may be formed by procedures well known and described in the art.
  • Other acids such as oxalic acid, which may not be considered pharmaceutically acceptable, may be useful in the preparation of salts useful as intermediates in obtaining a deuterated analog of the invention and its pharmaceutically acceptable acid addition salt.
  • Examples of pharmaceutically acceptable cationic salts of a deuterated analog of the invention include, without limitation, the sodium, the potassium, the calcium, the magnesium, the zinc, the aluminium, the lithium, the choline, the lysinium, and the ammonium salt, and the like, of a deuterated analog of the invention containing an anionic group. Such cationic salts may be formed by procedures well known and described in the art.
  • The deuterated analog of the invention may be provided in dissoluble or indissoluble forms together with a pharmaceutically acceptable solvent such as water, ethanol, and the like. Dissoluble forms may also include hydrated forms such as the monohydrate, the dihydrate, the hemihydrate, the trihydrate, the tetrahydrate, and the like. In general, the dissoluble forms are considered equivalent to indissoluble forms for the purposes of this invention.
    • Methods Of Preparation
  • The deuterated analog of the invention may be prepared by conventional methods for chemical synthesis, e.g. those described in the working examples. The starting materials for the processes described in the present application are known or may readily be prepared by conventional methods from commercially available chemicals.
  • Also one compound of the invention may be converted to another compound of the invention using conventional methods.
  • The end products of the reactions described herein may be isolated by conventional techniques, e.g. by extraction, crystallisation, distillation, chromatography, etc.
    • Biological Activity
  • WO 01/46145, WO 01/46146, WO 2005/121087, WO 2007/042295 WO 2008/127188 and WO 2008/155357 all describe substituted 4-phenyl-N-alkyl-piperazines and 4-phenyl-N-alkyl-piperidines, reported to be modulators of dopamine neurotransmission, and to be useful in treatment of symptoms of various disorders of the central nervous system. The deuterated analog of the invention is considered useful for the same medical indications as described in these publications, and these publications therefore are incorporated by reference.
  • Neurological indications contemplated according to these publications include the treatment of Huntington's disease and other movement disorders, as well as movement disorders induced by drugs.
  • Therefore, in a preferred embodiment, the invention relates to the use of the deuterated analog of the invention for use as a medicament for the treatment of Huntington's disease.
    • Pharmaceutical Compositions
  • Viewed from another aspect the invention provides deuterated analogs for use as medicaments. Therefore, in another aspect, the invention provides novel pharmaceutical compositions comprising a therapeutically effective amount of the compound of the invention.
  • While a deuterated analog of the invention for use in therapy may be administered in the form of the raw compound, it is preferred to introduce the active ingredient, optionally in the form of a physiologically acceptable salt, in a pharmaceutical composition together with one or more adjuvants, excipients, carriers, buffers, diluents, and/or other customary pharmaceutical auxiliaries.
  • Pharmaceutical compositions of the invention may in particular be formulated as described in WO 01/46145.
  • Further details on techniques for formulation and administration may be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing Co., Easton, Pa.).
  • The dose administered must of course be carefully adjusted to the age, weight and condition of the individual being treated, as well as the route of administration, dosage form and regimen, and the result desired, and the exact dosage should of course be determined by the practitioner.
  • The actual dosage depends on the nature and severity of the disease being treated, and is within the discretion of the physician, and may be varied by titration of the dosage to the particular circumstances of this invention to produce the desired therapeutic effect. However, it is presently contemplated that pharmaceutical compositions containing of from about 1 to about 500 mg of active ingredient per individual dose, preferably of from about 10 to about 100 mg, most preferred of from about 25 to about 50 mg, are suitable for therapeutic treatments. The daily dose will preferably be administered in individual dosages 1 to 4 times daily.
    • Methods Of Therapy
  • In another aspect the invention provides a method for the treatment, prevention or alleviation of a dopamine mediated disorder of a living animal body, including a human, which method comprises the step of administering to such a living animal body in need thereof a therapeutically effective amount of the deuterated analog of the invention.
  • In a preferred embodiment the dopamine mediated disorder is Huntington's disease.
    • EXAMPLES
  • The invention is further illustrated in the examples below, which in no way are intended to limit the scope of the invention.
    • Example 1 Preparatory Example
  • 4-(3-Methanesulfonyl-phenyl)-1-propyl-d7-piperidine x HCl
  • 4-(3-Methanesulfonyl-phenyl)-piperidine (0.43 g), CH3CN (4 ml), K2CO3 (0.49 g), and 1-lodopropane-d7 (0.19 g) are mixed and heated in microwave oven for 30 min at 120° C. The mixture is filtered and evaporated to dryness and purified on silica column using iso-octane:EtOAc (1:1) containing 5% NEt3 as eluent. After evaporation of the fractions with pure product, the residue is re-dissolved in EtOAc and washed with a 10% Na2CO3 solution. The organic phase is separated and dried with Na2SO4, filtered and evaporated to yield pure product (0.33 g). The amine is then converted to the HCl salt, and re-crystallized from EtOH:Et2O. M.p. 198-199° C.

Claims (21)

1-11. (canceled)
12. A pharmaceutical composition comprising a compound represented by Formula 1
Figure US20160166559A1-20160616-C00002
or a pharmaceutically acceptable salt thereof, wherein
at least one of R1-R23 represents deuterium (D); and
the remaining of R1-R23 represent hydrogen (H);
wherein the abundance of molecules of the compound having deuterium at a position designated by the at least one of R1-R23 is substantially greater than the natural abundance of deuterium at that position.
13. The pharmaceutical composition of claim 12, wherein
R1-R2 represent deuterium (D); and
all of R3-R23 represent hydrogen (H).
14. The pharmaceutical composition of claim 12, wherein at least one of R1-R7 represents deuterium (D); and
the remaining of R1-R23 represent hydrogen (H).
15. The pharmaceutical composition of claim 12, wherein
all of R1-R7 represent deuterium (D); and
all of R8-R23 represent hydrogen (H).
16. The pharmaceutical composition of claim 12, wherein
R8, R9, R10 and R11 represent deuterium (D); and
all of R1-R7 and R12-R23 represent hydrogen (H).
17. The pharmaceutical composition of claim 12, wherein
R12 represents deuterium (D); and
all of R1-R11 and R13-R23 represent hydrogen (H).
18. The pharmaceutical composition of claim 12, wherein
R17-R20 represent deuterium (D); and
all of R1-R16 and R21-R23 represent hydrogen (H).
19. The pharmaceutical composition of claim 12, wherein the compound or the pharmaceutically acceptable salt thereof is 4-(3-Methanesulfonyl-phenyl)-1-propyl-d7-piperidine hydrochloride.
20. The pharmaceutical composition of claim 12, wherein the abundance of molecules of the compound having deuterium at a position designated by the at least one of R1-R23 is at least 3,340 times greater than the natural abundance of deuterium at that position, at least 3,500 times greater than the natural abundance of deuterium at that position, at least 4,000 times greater than the natural abundance of deuterium at that position, at least 5,000 times greater than the natural abundance of deuterium at that position, at least 6,000 times greater than the natural abundance of deuterium at that position, at least 6,466.7 times greater than the natural abundance of deuterium at that position, or at least 6,633.3 times greater than the natural abundance of deuterium at that position.
21. The pharmaceutical composition of claim 12, comprising the pharmaceutically acceptable salt of the compound.
22. A therapeutically effective amount of the pharmaceutical composition of claim 12 together with at least one pharmaceutically acceptable carrier, excipient or diluent.
23. The pharmaceutical composition according to claim wherein
R1-R2 represent deuterium (D); and
all of R3-R23 represent hydrogen (H).
24. The pharmaceutical composition according to claim 22, wherein
at least one of R1-R7 represents deuterium (D); and
the remaining of R1-R23 represent hydrogen (H).
25. The pharmaceutical composition according to claim 22, wherein
all of R1-R7 represent deuterium (D); and
all of R8- R23 represent hydrogen (H).
26. The pharmaceutical composition according to claim 22, wherein
R8, R9, R10 and R11 represent deuterium (D); and
all of R1-R7 and R12-R23 represent hydrogen (H).
27. The pharmaceutical composition according to claim 22, wherein
R12 represents deuterium (D); and
all of R1-R11 and R13-R23 represent hydrogen (H).
28. The pharmaceutical composition according to claim 22, wherein
R17- R20 represent deuterium (D); and
all of R1-R16 and R21-R23 represent hydrogen (H).
29. The pharmaceutical composition of claim 22 comprising the pharmaceutically acceptable salt of the compound.
30. A method of treating, preventing, or alleviating a symptom of, a dopamine mediated disorder in a living animal which comprises administering to the living animal a therapeutically effective amount of the pharmaceutical composition of claim 12.
31. A method of treating, or alleviating a symptom of, Huntington's Disease in a living animal which comprises administering to the living animal a therapeutically effective amount of the pharmaceutical composition of claim 12.
US14/968,522 2010-09-03 2015-12-14 Deuterated analogs of pridopidine useful as dopaminergic stabilizers Abandoned US20160166559A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US14/968,522 US20160166559A1 (en) 2010-09-03 2015-12-14 Deuterated analogs of pridopidine useful as dopaminergic stabilizers
US15/960,041 US20180235950A1 (en) 2010-09-03 2018-04-23 Deuterated analogs of pridopidine useful as dopaminergic stabilizers
US16/133,192 US10799492B2 (en) 2010-09-03 2018-09-17 Deuterated analogs of pridopidine useful as dopaminergic stabilizers

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DKPA201070385 2010-09-03
DKPA201070385 2010-09-03
US38085110P 2010-09-08 2010-09-08
PCT/EP2011/064954 WO2012028635A1 (en) 2010-09-03 2011-08-31 Deuterated analogs of pridopidine useful as dopaminergic stabilizers
US201313820024A 2013-04-10 2013-04-10
US14/968,522 US20160166559A1 (en) 2010-09-03 2015-12-14 Deuterated analogs of pridopidine useful as dopaminergic stabilizers

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2011/064954 Continuation WO2012028635A1 (en) 2010-09-03 2011-08-31 Deuterated analogs of pridopidine useful as dopaminergic stabilizers
US13/820,024 Continuation US20130197031A1 (en) 2010-09-03 2011-08-31 Deuterated analogs of pridopidine useful as dopaminergic stabilizers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/960,041 Continuation US20180235950A1 (en) 2010-09-03 2018-04-23 Deuterated analogs of pridopidine useful as dopaminergic stabilizers

Publications (1)

Publication Number Publication Date
US20160166559A1 true US20160166559A1 (en) 2016-06-16

Family

ID=44653278

Family Applications (5)

Application Number Title Priority Date Filing Date
US13/820,024 Abandoned US20130197031A1 (en) 2010-09-03 2011-08-31 Deuterated analogs of pridopidine useful as dopaminergic stabilizers
US14/968,510 Abandoned US20160095847A1 (en) 2010-09-03 2015-12-14 Deuterated analogs of pridopidine useful as dopaminergic stabilizers
US14/968,522 Abandoned US20160166559A1 (en) 2010-09-03 2015-12-14 Deuterated analogs of pridopidine useful as dopaminergic stabilizers
US15/960,041 Abandoned US20180235950A1 (en) 2010-09-03 2018-04-23 Deuterated analogs of pridopidine useful as dopaminergic stabilizers
US16/133,192 Active US10799492B2 (en) 2010-09-03 2018-09-17 Deuterated analogs of pridopidine useful as dopaminergic stabilizers

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US13/820,024 Abandoned US20130197031A1 (en) 2010-09-03 2011-08-31 Deuterated analogs of pridopidine useful as dopaminergic stabilizers
US14/968,510 Abandoned US20160095847A1 (en) 2010-09-03 2015-12-14 Deuterated analogs of pridopidine useful as dopaminergic stabilizers

Family Applications After (2)

Application Number Title Priority Date Filing Date
US15/960,041 Abandoned US20180235950A1 (en) 2010-09-03 2018-04-23 Deuterated analogs of pridopidine useful as dopaminergic stabilizers
US16/133,192 Active US10799492B2 (en) 2010-09-03 2018-09-17 Deuterated analogs of pridopidine useful as dopaminergic stabilizers

Country Status (17)

Country Link
US (5) US20130197031A1 (en)
EP (1) EP2611759A1 (en)
JP (1) JP2013536825A (en)
KR (1) KR20140008297A (en)
CN (1) CN103249697B (en)
AU (2) AU2011298382A1 (en)
BR (1) BR112013005125A2 (en)
CA (1) CA2810092A1 (en)
CL (1) CL2013000604A1 (en)
EA (1) EA201390332A1 (en)
IL (1) IL224776A (en)
MX (1) MX2013002453A (en)
NZ (1) NZ608120A (en)
PE (1) PE20140105A1 (en)
SG (2) SG10201506761XA (en)
WO (1) WO2012028635A1 (en)
ZA (1) ZA201301902B (en)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9796673B2 (en) 2014-12-22 2017-10-24 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
US9814706B2 (en) 2011-12-08 2017-11-14 Teva Pharmaceuticals International Gmbh Hydrobromide salt of pridopidine
WO2018053280A1 (en) 2016-09-16 2018-03-22 Teva Pharmaceuticals International Gmbh Use of pridopidine for treating rett syndrome
WO2018136600A1 (en) 2017-01-20 2018-07-26 Teva Pharmaceuticals International Gmbh Use of pridopidine for the treatment of fragile x syndrome
US10047049B2 (en) 2015-07-22 2018-08-14 Teva Pharmaceuticals International Gmbh Process for preparing pridopidine
US10130621B2 (en) 2014-06-30 2018-11-20 Teva Pharmaceutical Industries Ltd. Analogs of pridopidine, their preparation and use
WO2019036358A1 (en) 2017-08-14 2019-02-21 Teva Pharmaceuticals International Gmbh Method of treating amyotrophic lateral sclerosis with pridopidine
WO2019046568A1 (en) 2017-08-30 2019-03-07 Teva Pharmaceuticals International Gmbh High copncentration dosage forms of pridopidine
WO2019050775A1 (en) 2017-09-08 2019-03-14 Teva Pharmaceuticals International Gmbh Pridopidine for treating drug induced dyskinesias
US10322119B2 (en) 2013-06-21 2019-06-18 Prilenia Therapeutics Development Ltd. Use of pridopidine for treating Huntington's disease
US10459055B2 (en) * 2017-04-07 2019-10-29 Case Western Reserve University System and method for reduced field of view MR fingerprinting for parametric mapping
US10603311B2 (en) 2015-02-25 2020-03-31 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
US10799492B2 (en) 2010-09-03 2020-10-13 Prilenia Neurotherapeutics Ltd. Deuterated analogs of pridopidine useful as dopaminergic stabilizers
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
US11207308B2 (en) 2012-04-04 2021-12-28 Prilenia Neurotherapeutics Ltd. Pharmaceutical compositions for combination therapy
US11207310B2 (en) 2016-08-24 2021-12-28 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating functional decline
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
US11738012B2 (en) 2016-02-24 2023-08-29 Prilenia Neurotherapeutics Ltd. Treatment of neurodegenerative eye disease using pridopidine
US11826361B2 (en) 2016-08-24 2023-11-28 Prilenia Neurotherapeutics Ltd Use of pridopidine for treating dystonias

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
EP2146961B1 (en) * 2007-04-12 2014-01-29 IVAX International GmbH N-oxide and/or di-n-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles
EA023462B1 (en) 2011-09-07 2016-06-30 Тева Фармасьютикалз Интернэшнл Гмбх Polymorphic form of pridopidine hydrochloride
IN2015DN01662A (en) 2012-09-18 2015-07-03 Auspex Pharmaceuticals Inc
EA201691582A1 (en) 2014-02-07 2017-01-30 Оспекс Фармасьютикалз, Инк. NEW PHARMACEUTICAL PREPARATIONS
PL3265085T3 (en) 2015-03-06 2022-11-07 Auspex Pharmaceuticals, Inc. Methods for the treatment of abnormal involuntary movement disorders
US11597726B2 (en) 2020-05-20 2023-03-07 Certego Therapeutics Inc. Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110206782A1 (en) * 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US6440710B1 (en) * 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
DE60001623T2 (en) * 1999-12-03 2003-12-18 Pfizer Prod Inc Sulfamoyl heteroaryl pyrazole compounds for use as an analgesic / anti-inflammatory agent
SE9904724D0 (en) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
SE9904723D0 (en) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
DE10123129A1 (en) * 2001-05-02 2002-11-14 Berolina Drug Dev Ab Svedala Deuterated 3-piperidinopropiophenones and medicinal products containing these compounds
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
US7004629B2 (en) 2003-07-26 2006-02-28 Arthur Joseph Shrader Method and apparatus for hanging a resealable bag
DK1773772T3 (en) 2004-06-08 2010-09-13 Nsab Af Neurosearch Sweden Ab Novel disubstituted phenylpiperidines / piperazines as modulators of dopamine neurotransmission
EP1802573B1 (en) 2004-10-13 2016-09-28 Teva Pharmaceuticals International GmbH Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine
CN101309917B (en) * 2005-10-06 2013-09-11 奥斯拜客斯制药有限公司 Inhibitors of the gastric h+, k+-atpase with enhanced therapeutic properties
SE529246C2 (en) 2005-10-13 2007-06-12 Neurosearch Sweden Ab New disubstituted phenyl-piperidines as modulators of dopamine neurotransmission
CN101360742A (en) * 2005-11-14 2009-02-04 奥斯拜客斯制药有限公司 Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
EP1948646A2 (en) 2005-11-14 2008-07-30 Auspex Pharmaceuticals Inc. Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
US7750168B2 (en) * 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
EP2146961B1 (en) 2007-04-12 2014-01-29 IVAX International GmbH N-oxide and/or di-n-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles
EP2170327B1 (en) 2007-06-18 2014-10-22 A.Carlsson Research AB Use of dopamine stabilizers
US8288414B2 (en) * 2007-09-12 2012-10-16 Deuteria Pharmaceuticals, Inc. Deuterium-enriched lenalidomide
EP2611759A1 (en) 2010-09-03 2013-07-10 Ivax International Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
EA023462B1 (en) 2011-09-07 2016-06-30 Тева Фармасьютикалз Интернэшнл Гмбх Polymorphic form of pridopidine hydrochloride
US9012476B2 (en) 2011-12-08 2015-04-21 IVAX International GmbH Hydrobromide salt of pridopidine
EA027748B1 (en) 2012-04-04 2017-08-31 Тева Фармасьютикалз Интернэшнл Гмбх Use of pridopidine in combination with tetrabenazine for treating movement disorders and obesity
IN2015DN03219A (en) 2012-09-27 2015-10-02 Teva Pharma
US20150216850A1 (en) 2012-09-27 2015-08-06 Michael Hayden Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
AU2014281414A1 (en) 2013-06-21 2016-01-21 Teva Pharmaceuticals International Gmbh Use of high dose pridopidine for treating Huntington's disease
ES2911800T3 (en) 2014-01-22 2022-05-20 Prilenia Neurotherapeutics Ltd Modified release formulations of pridopidine
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
JP2018505147A (en) 2014-12-22 2018-02-22 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハー L-tartrate of pridopidine
US10603311B2 (en) 2015-02-25 2020-03-31 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
US20170020854A1 (en) 2015-07-22 2017-01-26 Teva Pharmaceuticals International Gmbh Pridopidine base formulations and their use
AR105434A1 (en) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh PROCESS TO PREPARE PRIDOPIDINE
US20170026730A1 (en) 2015-07-23 2017-01-26 Knowles Electronics, Llc Microphone with temperature sensor
US11738012B2 (en) 2016-02-24 2023-08-29 Prilenia Neurotherapeutics Ltd. Treatment of neurodegenerative eye disease using pridopidine
CA3035099C (en) 2016-08-24 2023-01-17 Prilenia Therapeutics Development Ltd. Use of pridopidine for treating dystonias
CA3035092C (en) 2016-08-24 2022-05-31 Prilenia Therapeutics Development Ltd. Use of pridopidine for treating functional decline
AU2017326436A1 (en) 2016-09-15 2019-04-11 Prilenia Neurotherapeutics Ltd Use of pridopidine for the treatment of anxiety and depression
US11111482B2 (en) 2016-09-16 2021-09-07 Cargill, Incorporated Genetically modified lactate-consuming yeasts and fermentation processes using such genetically modified yeasts
WO2018053275A1 (en) 2016-09-16 2018-03-22 Teva Pharmaceuticals International Gmbh Use of pridopidine for the treatment of familial dysautonomia
CN110505902B (en) 2017-01-20 2022-11-11 普瑞尼亚神经治疗有限公司 Use of pridopidine for the treatment of fragile X syndrome
MX2020001836A (en) 2017-08-14 2020-08-10 Prilenia Neurotherapeutics Ltd Method of treating amyotrophic lateral sclerosis with pridopidine.
NL2019473B1 (en) 2017-09-01 2019-03-11 Isobionics B V Terpene Synthase producing patchoulol and elemol, and preferably also pogostol
MX2020002645A (en) 2017-09-08 2021-06-10 Prilenia Neurotherapeutics Ltd Pridopidine for treating drug induced dyskinesias.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110206782A1 (en) * 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DUFF, K. et al. Psychiatric Symptoms in Huntington's Disease before Diagnosis: The Predict-HD Study. Biological Psychiatry. 2007, Vol. 62, page 1341. *
DYCK, LE. et al. Effects of Deuterium Substitution on the Catabolism of beta-Phenylethylamine: An In Vivo Study, Journal of Neurochemistry. 1986, Vol. 46, page 399. *
OWALKER, F. Huntington's disease. Lancet. 2007, Vol. 369, page 218. *

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10799492B2 (en) 2010-09-03 2020-10-13 Prilenia Neurotherapeutics Ltd. Deuterated analogs of pridopidine useful as dopaminergic stabilizers
US9814706B2 (en) 2011-12-08 2017-11-14 Teva Pharmaceuticals International Gmbh Hydrobromide salt of pridopidine
US11207308B2 (en) 2012-04-04 2021-12-28 Prilenia Neurotherapeutics Ltd. Pharmaceutical compositions for combination therapy
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
US10322119B2 (en) 2013-06-21 2019-06-18 Prilenia Therapeutics Development Ltd. Use of pridopidine for treating Huntington's disease
US11141412B2 (en) 2014-06-30 2021-10-12 Prilenia Neurotherapeutics Ltd. Analogs of pridopidine, their preparation and use
US10406145B2 (en) 2014-06-30 2019-09-10 Prilenia Neurotherapeutics Ltd. Analogs of pridopidine, their preparation and use
US10130621B2 (en) 2014-06-30 2018-11-20 Teva Pharmaceutical Industries Ltd. Analogs of pridopidine, their preparation and use
US9796673B2 (en) 2014-12-22 2017-10-24 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
US10603311B2 (en) 2015-02-25 2020-03-31 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
US10047049B2 (en) 2015-07-22 2018-08-14 Teva Pharmaceuticals International Gmbh Process for preparing pridopidine
US11738012B2 (en) 2016-02-24 2023-08-29 Prilenia Neurotherapeutics Ltd. Treatment of neurodegenerative eye disease using pridopidine
US11207310B2 (en) 2016-08-24 2021-12-28 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating functional decline
US11826361B2 (en) 2016-08-24 2023-11-28 Prilenia Neurotherapeutics Ltd Use of pridopidine for treating dystonias
EP4005570A1 (en) 2016-09-16 2022-06-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
WO2018053280A1 (en) 2016-09-16 2018-03-22 Teva Pharmaceuticals International Gmbh Use of pridopidine for treating rett syndrome
WO2018136600A1 (en) 2017-01-20 2018-07-26 Teva Pharmaceuticals International Gmbh Use of pridopidine for the treatment of fragile x syndrome
US11234973B2 (en) 2017-01-20 2022-02-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for the treatment of fragile X syndrome
US10459055B2 (en) * 2017-04-07 2019-10-29 Case Western Reserve University System and method for reduced field of view MR fingerprinting for parametric mapping
WO2019036358A1 (en) 2017-08-14 2019-02-21 Teva Pharmaceuticals International Gmbh Method of treating amyotrophic lateral sclerosis with pridopidine
US11406625B2 (en) 2017-08-14 2022-08-09 Prilenia Neurotherapeutics Ltd. Method of treating amyotrophic lateral sclerosis with pridopidine
EP4154882A1 (en) 2017-08-14 2023-03-29 Prilenia Neurotherapeutics Ltd. Treating amyotrophic lateral sclerosis with pridopidine
WO2019046568A1 (en) 2017-08-30 2019-03-07 Teva Pharmaceuticals International Gmbh High copncentration dosage forms of pridopidine
US11452694B2 (en) 2017-08-30 2022-09-27 Prilenia Neurotherapeutics Ltd. High concentration dosage forms of pridopidine
US11000519B2 (en) 2017-09-08 2021-05-11 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
WO2019050775A1 (en) 2017-09-08 2019-03-14 Teva Pharmaceuticals International Gmbh Pridopidine for treating drug induced dyskinesias

Also Published As

Publication number Publication date
CN103249697A (en) 2013-08-14
US10799492B2 (en) 2020-10-13
US20160095847A1 (en) 2016-04-07
CA2810092A1 (en) 2012-03-08
US20130197031A1 (en) 2013-08-01
KR20140008297A (en) 2014-01-21
NZ608120A (en) 2014-12-24
AU2016250390A1 (en) 2016-11-10
BR112013005125A2 (en) 2016-08-16
WO2012028635A1 (en) 2012-03-08
US20180235950A1 (en) 2018-08-23
CN103249697B (en) 2016-06-15
US20190015401A1 (en) 2019-01-17
MX2013002453A (en) 2013-08-01
PE20140105A1 (en) 2014-02-14
EA201390332A1 (en) 2013-08-30
CL2013000604A1 (en) 2013-11-15
AU2011298382A1 (en) 2013-05-02
EP2611759A1 (en) 2013-07-10
ZA201301902B (en) 2014-05-28
IL224776A (en) 2017-07-31
JP2013536825A (en) 2013-09-26
SG188298A1 (en) 2013-04-30
SG10201506761XA (en) 2015-10-29

Similar Documents

Publication Publication Date Title
US10799492B2 (en) Deuterated analogs of pridopidine useful as dopaminergic stabilizers
AU2014292722B2 (en) Quinine compounds, and optical isomers, preparation method and medical use thereof
US10280158B2 (en) Immune adjustment compound, use thereof and pharmaceutical composition comprising same
US9156826B2 (en) Asymmetrical reversible neuromuscular blocking agents of ultra-short, short, or intermediate duration
JP2015510916A (en) Use of pyrazole derivatives in the treatment of acute exacerbations of chronic obstructive pulmonary disease
JP2008179541A (en) Therapeutic agent for neuropathic pain
JP2010514734A (en) Isosorbide mononitrate derivatives for the treatment of intestinal disorders
EA022909B1 (en) Benzothiazolone compound
US9457018B2 (en) Method for combating adverse effects arising from antipsychotic treatment
JPH0269417A (en) Schizophrenia treatment composition
US20110306633A1 (en) Selective m4 receptor antagonist and its medical use
US9125916B2 (en) Methods of treating hypertrophic cardiomyopathy
US8168632B2 (en) Bicyclic amide derivatives for the treatment of respiratory disorders
US9745275B2 (en) Pain-related compound and medical composition
JP2005060311A (en) Neuropathic pain-treating agent containing n-(benzoyl)amino acid derivative as active ingredient
JP3681770B2 (en) Treatment for senile dementia or Alzheimer's disease
WO2023141207A1 (en) Esters of 8-methyl-8-azabicyclo[3.2.1] octan-3-yl 3-hydroxy-2-phenylpropanoate
AU2021359042B1 (en) Compound as potassium channel regulator and preparation and use thereof
JP4888751B2 (en) Trifluoropropylaminopentane derivative and method for producing the same

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION